Holen Sie sich die Stockscreener-App
0.23
3.56%
-0.0085
Handel nachbörslich:
.23
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MRNS?
Forum
Prognose
Aktiensplit
Marinus Pharmaceuticals Inc Aktie (MRNS) Neueste Nachrichten
Marinus Pharma stock hits 52-week low at $0.23 - Investing.com India
Marinus Pharma stock hits 52-week low at $0.23 By Investing.com - Investing.com Australia
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Marinus Pharmaceuticals' SWOT analysis: epilepsy drug maker's stock faces pivotal moment - Investing.com
Marinus Pharma stock hits 52-week low at $0.26 amid steep decline - Investing.com
Marinus Pharma stock hits 52-week low at $0.26 amid steep decline By Investing.com - Investing.com South Africa
Marinus Pharmaceuticals faces Nasdaq delisting risk - Investing.com
Marinus Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com Nigeria
Marinus Pharmaceuticals' SWOT analysis: stock faces challenges amid pipeline setbacks By Investing.com - Investing.com South Africa
Marinus Pharmaceuticals' SWOT analysis: stock faces challenges amid pipeline setbacks - Investing.com India
MRNS (Marinus Pharmaceuticals) Enterprise Value : $31.67 Mil (As of Dec. 02, 2024) - GuruFocus.com
MRNS (Marinus Pharmaceuticals) Revenue per Share : $0.55 (TTM As of Sep. 2024) - GuruFocus.com
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MR - GuruFocus.com
MRNS (Marinus Pharmaceuticals) Net Income : $-140.49 Mil (TTM As of Sep. 2024) - GuruFocus.com
Marinus Pharmaceuticals (LTS:0JYL) COGS-to-Revenue : 0.08 (As of Sep. 2024) - GuruFocus.com
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investor - GuruFocus.com
CDKL5 Deficiency Disorder Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Marinus Pharma, Takeda, Zogenix, Inc., UCB, Ultragenyx Pharma - The Globe and Mail
CDKL5 Deficiency Disorder Market Revenue to Expand - openPR
Marinus Pharmaceuticals Reports Q3 2024 Financial Results and Strategic Developments - MSN
MRNS (Marinus Pharmaceuticals) Degree of Operating Leverage : 65.26 (As of Jun. 2024) - GuruFocus.com
Marinus Pharmaceuticals Third Quarter 2024 Earnings: Revenues Disappoint - Simply Wall St
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results - Yahoo Finance
Marinus Pharmaceuticals Lays Off 45% of Employees - BioSpace
Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit - TipRanks
Marinus Pharmaceuticals Reports Q3 Growth in ZTALMY Revenue - TipRanks
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Marinus Pharmaceuticals' SWOT analysis: navigating challenges in rare epilepsy stock - Investing.com India
Marinus Pharmaceuticals: Q3 Earnings Snapshot - Darien Times
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates - MSN
Marinus Pharmaceuticals Inc Reports Q3 2024 Revenue of $8.54M, G - GuruFocus.com
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment - Investing.com Canada
Greenlane Holdings to Distribute CURB’s Innovative Inhalation Device: A Game-Changer? - BP Journal
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment By Investing.com - Investing.com South Africa
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):